Pharmaceutical Industry Antitrust Handbook

The Handbook provides an overview of the pharmaceutical industry, including the market participants, FDA regulatory structure, and background on private litigation and government enforcement.

Select a format

eBook :epub
2nd Edition
ISBN: 9781641052146
In Stock
Price
$249.00
QTY
eBook :mobi
2nd Edition
ISBN: 9781641052146
In Stock
Price
$249.00
QTY
International Order Inquiry

Product details

View a sample of this title using the ReadNow feature

With pharmaceuticals representing such an important part of the nation's economy and the health care sector, competition in the pharmaceutical industry is crucial to provide the best quality drugs for the lowest possible price. Antitrust enforcement plays a key role in ensuring competition in this industry. The past decade has featured numerous high-profile decisions, including that of the Supreme Court in FTC v. Actavis, that have fundamentally influenced the advice that practitioners give to their pharmaceutical clients.

Written for the antitrust and pharmaceutical communities, the Pharmaceutical Industry Antitrust Handbook, Second Edition is intended to provide a comprehensive and objective source about the most important antitrust issues faced by the pharmaceutical industry today. The Handbook provides an overview of the pharmaceutical industry, including the market participants, FDA regulatory structure, and background on private litigation and government enforcement. It then addresses the substantive antitrust issues presented by mergers and acquisition, joint ventures, various forms of potentially anticompetitive conduct, and distribution. Finally, it discusses the kinds of economic data that are integral to antitrust analysis for this industry.

eBooks, CDs, downloadable content, and software purchases are non-cancellable, nonrefundable and nonreturnable. Click here for more information about LexisNexis eBooks. The eBook versions of this title may feature links to Lexis Advance® for further legal research options. A valid subscription to Lexis Advance® is required to access this content.